Brazil Codifies Cancer-Drug Access and Localizes Pembrolizumab Manufacturing Under New Law
Law 15.385/2026 mandates SUS incorporation of CONITEC-approved oncology drugs while a Fiocruz-MSD partnership delivers 100% domestically produced pembrolizumab, reducing Brazil’s import dependence for a flagship immunotherapy.
Codified access mandates and domestic biologic manufacturing rarely arrive together. In Brazil, they just did. Law 15.385/2026, signed by the federal government, requires the Unified Health System to incorporate oncology medicines that have received a positive recommendation from CONITEC — the national health technology assessment body — into the public formulary. Simultaneously, the Ministry of Health has confirmed that a product development partnership between Fiocruz and MSD has achieved 100% domestic production of pembrolizumab, the checkpoint inhibitor that has reshaped oncology treatment globally, according to the Ministry of Health’s announcement.
The two developments are legally and operationally distinct. Together, however, they suggest a deliberate policy architecture: mandate the access pathway by statute, then reduce the supply-chain vulnerability that has historically constrained it.
System Implications
Prior to Law 15.385/2026, the incorporation of CONITEC-recommended drugs into SUS coverage operated through administrative processes that did not carry a statutory deadline or legal obligation. The new law changes that structure. According to the Casa Civil announcement, the legislation institutes a regulatory framework specifically for high-cost cancer vaccines and medicines, establishing incorporation of CONITEC-approved oncology therapies as a legal requirement rather than a discretionary administrative act.
The practical implication is that a positive CONITEC recommendation now carries binding downstream consequences for SUS formulary inclusion. This shifts the locus of access decisions: a favorable HTA outcome is no longer a necessary but insufficient condition — it becomes, under the new framework, a legally operative trigger. Further data is needed to assess the specific timelines and procedural mechanisms the law establishes between CONITEC approval and formal SUS incorporation.
Patient Access
The Fiocruz-MSD partnership delivers pembrolizumab through Brazil’s established PDP mechanism, a technology-transfer model designed to localize production of strategic medicines within the national industrial base. According to the Ministry of Health, the partnership has reached 100% domestic production of the immunotherapy. The Ministry further indicates that the domestic supply is positioned to expand pembrolizumab’s eligible indications within SUS beyond its current melanoma coverage.
For patients, the operational significance is supply security. Import-dependent biologics are exposed to currency fluctuation, logistics disruption, and bilateral trade conditions. A domestically manufactured supply chain reduces those exposure points, though the Ministry’s announcement does not specify production volumes, pricing terms under the PDP, or the timeline for indication expansion approvals through CONITEC.
Industry and Payer Implications
For multinational pharmaceutical manufacturers with oncology portfolios seeking SUS access, the Fiocruz-MSD PDP represents a structural precedent. The model — in which a global manufacturer transfers technology to Fiocruz in exchange for a supply agreement with the public system — has existed in Brazil for vaccines and antiretrovirals. Its extension into immuno-oncology, a category characterized by high unit costs and complex biologics manufacturing, marks a meaningful expansion of the model’s scope.
Manufacturers monitoring Brazil’s oncology market will need to assess whether the PDP pathway is becoming an implicit condition for sustained formulary presence in high-volume indications. The law’s incorporation mandate creates a more predictable access pathway, but it also concentrates negotiating leverage at the CONITEC recommendation stage — the point at which HTA outcomes, pricing negotiations, and PDP commitments are likely to intersect. Payers within the SUS structure face a corresponding obligation: once the statutory trigger is met, budget allocation for newly mandated therapies becomes a legal requirement, not a planning option. Health services and state-level SUS administrators should assess formulary update cycles and procurement planning timelines in light of the new mandatory incorporation framework.
Regulatory and Legal Considerations
Law 15.385/2026 is confirmed legislation, per the Casa Civil announcement. The regulatory framework it establishes for high-cost oncology medicines is in force. The specific implementing regulations — including procedural timelines, budget allocation mechanisms, and the operational interface between CONITEC recommendations and SUS procurement — have not yet been published, and the full regulatory architecture remains subject to secondary rulemaking.
The Fiocruz-MSD PDP is confirmed as operational, with 100% domestic production reported by the Ministry of Health. The indication expansion beyond melanoma referenced in the Ministry’s announcement has not yet been confirmed as a completed CONITEC process — it appears to represent a stated objective of the partnership rather than a finalized regulatory outcome.
Counterpoint
The principal counterargument is budgetary, not procedural. A statutory mandate to incorporate CONITEC-approved oncology drugs does not automatically resolve the fiscal gap between a legal obligation and available SUS appropriations. Brazil’s public health system operates under chronic resource constraints, and oncology biologics — including checkpoint inhibitors — carry among the highest per-patient costs in the formulary. A binding incorporation mandate without a corresponding dedicated funding mechanism could produce a situation in which legal entitlement outpaces actual dispensing capacity, shifting the access bottleneck from regulatory approval to budget execution.
The PDP model addresses unit cost over time through domestic production, but the transition period — during which import costs may still apply to portions of supply — and the capital requirements of scaling biologic manufacturing at Fiocruz represent real financial variables. The Ministry’s announcement does not detail the cost structure of the PDP agreement or the pricing terms under which pembrolizumab will be supplied to SUS, leaving the fiscal sustainability of the model incompletely characterized by available sources.
Strategic Outlook
If the Fiocruz-MSD PDP performs as described and the indication expansion proceeds through CONITEC, one possible scenario is that Brazil’s immuno-oncology access profile within SUS broadens materially over the next regulatory cycle. The statutory incorporation mandate would then function as the mechanism converting those CONITEC decisions into formulary reality with reduced administrative friction.
For other IO manufacturers — particularly those with checkpoint inhibitors or combination regimens under CONITEC review — the strategic question is whether a PDP commitment accelerates or conditions a favorable HTA outcome. The available signal does not confirm a formal linkage, but the sequencing of the MSD partnership and the legislative framework suggests the two policy instruments are being deployed in coordination rather than independently.
Absent further implementing regulation, the law’s full operational effect on incorporation timelines remains uncertain. The pace at which secondary rulemaking defines procedural deadlines will determine whether the statutory mandate produces near-term formulary changes or a longer administrative transition.
What to Watch
Secondary regulations implementing Law 15.385/2026: specifically, whether procedural timelines between CONITEC approval and SUS incorporation are defined and how budget allocation obligations are structured.
CONITEC review calendar for pembrolizumab indication expansions beyond melanoma, and whether the Fiocruz-MSD domestic supply agreement is formally cited in those HTA submissions.
Whether additional multinational manufacturers with high-cost oncology biologics initiate PDP negotiations with Fiocruz or other Brazilian public laboratories, signaling that the MSD model is being replicated.
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
You're in. The next Brief lands in your inbox.
Closing Insight
The deeper structural shift may be less about any single drug or law and more about where in the value chain Brazil is asserting control: by combining a statutory access mandate with domestic manufacturing, the government is effectively decoupling SUS oncology coverage decisions from the import economics that have historically constrained them — a configuration that, if sustained, alters the negotiating geometry for every high-cost biologic seeking public-system entry in Brazil.
Policy Intelligence
Brazil’s Cancer Access & Localization Pathway — Key Milestones
2023 — GECEIS Launch
Brazil establishes the Executive Group for the Health Economic-Industrial Complex (GECEIS), anchoring domestic production of medicines and health inputs as a state policy priority. PAHO designates Brazil the region’s highest-potential driver of health input self-sufficiency.
Fiocruz–MSD PDP — Pembrolizumab
Productive Development Partnership (PDP) between Fiocruz and MSD achieves 100% domestic manufacturing of pembrolizumab, reducing Brazil’s dependence on imported immunotherapy and lowering per-unit cost for SUS procurement.
Law 15.385/2026 — Codified Access
New federal law mandates SUS incorporation of all CONITEC-approved oncology drugs, converting discretionary access into a legal entitlement. Expedited pathways reduce lag between regulatory approval and patient availability across cancer indications.
Strategic Implication
Brazil’s dual-track model — codified access law plus localized manufacturing — sets a replicable template for LATAM markets. Pharma entrants face both a compliance obligation and a PDP negotiation imperative to secure long-term SUS formulary position.
Sources: PAHO/WHO Brazil, April 2023; Ministry of Health / Fiocruz; Law 15.385/2026 (Brazil)
A CVS Health white paper using Aetna claims data finds GLP-1s offset their full cost to plan sponsors only at $350 per month — well below current employer prices of $617–$766 monthly.
Pelacarsen reduced lipoprotein(a) (Lp(a)) by 78% in a Phase III trial of more than 8,300 adults yet produced no reduction in major adverse cardiovascular events, raising questions about whether lowering Lp(a) reduces them.
An international trial of 702 randomized adults found left bundle branch pacing (LBBP) lowered the hazard of death, heart failure hospitalization or pacing-induced cardiomyopathy by 59% (hazard ratio 0.41) versus right ventricular pacing (RVP); the …
New Institute for Health Metrics and Evaluation estimates show global health financing dropped 5% in 2026, following a 12% cut in 2025, as the UK posted the largest absolute reduction and low-income countries face the …